A Phase I Study of the Anti‐Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies

E-ISSN： 1545-5017|62|12|2120-2124

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.62, Iss.12, 2015-12, pp. : 2120-2124

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I/II study exploring ImMucin, a pan‐major histocompatibility complex, anti‐MUC1 signal peptide vaccine, in multiple myeloma patients

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 44-56

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 4, 2015-05 ,pp. : 528-533

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 5, 2015-09 ,pp. : 669-678

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies

By Awada Ahmad Zhang Steven Gil Thierry de Valeriola Dominique Lalami Yassine De Porre Peter Piccart-Gebhart Martine J.

Current Medical Research and Opinion, Vol. 23, Iss. 5, 2007-05 ,pp. : 991-1003

Informa Healthcare

Access to resources Recommend Favorite

A Phase I Study of the Optimized Cryptic Peptide TERT_572Y in Patients with Advanced Malignancies

Oncology, Vol. 70, Iss. 4, 2006-10 ,pp. : 306-314

Karger

Access to resources Recommend Favorite